Donald Trump left the board of his social media company weeks before federal subpoenas

Donald Trump left the board of his social media company weeks before federal subpoenas


The Truth social network logo is seen on a smartphone in front of a display of former U.S. President Donald Trump in this picture illustration taken February 21, 2022.

Dado Ruvic | Reuters

Former president Donald Trump left the board of his social media company just weeks before it was issued subpoenas by the Securities and Exchange Commission and a federal grand jury in Manhattan, records show.

Trump, who had served as the chairman of Trump Media and Technology Group, was one of six board members removed, according to a June 8 filing with the Florida Department of State’s Division of Corporations. His son Donald Trump Jr., also departed the board, along with Wes Moss, Kashyap Patel, Andrew Northwall and Scott Glabe. The news was first reported by the Sarasota Herald-Tribune.

The SEC served the company with a subpoena on June 27. Three days later, a federal grand jury in Manhattan issued a subpoena to the firm. Grand jury subpoenas typically indicate a criminal investigation is in progress.

The company said last week none of the subpoenas were directed at Trump. Representatives for Trump and for the company didn’t immediately return requests for comment Thursday.

The subpoenas appear to be related to a proposed merger between Trump Media and Technology and Digital World Acquisition Corp. DWAC disclosed the connection with a criminal probe last Friday. A week prior, DWAC said the government investigations could delay or even prevent its merger with Trump’s newly formed company, which includes Truth Social, a social media app intended to be an alternative to Twitter.

The Justice Department and the SEC, which regulates the stock market, are investigating the deal between DWAC and Trump Media. By merging with DWAC, which is a kind of shell company called a special purpose acquisition company, or SPAC, Trump’s firm would gain access to potentially billions of dollars on public equities markets.

Early criticism of the deal came from Sen. Elizabeth Warren in November. She wrote to SEC Chair Gary Gensler, telling him that DWAC “may have committed securities violations by holding private and undisclosed discussions about the merger as early as May 2021, while omitting this information in [SEC] filing and other public statements.”

Shares of DWAC were down less than a percent Thursday, but have fallen more than 50% so far this year.

—CNBC’s Mike Calia contributed to this report.



Source

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push
Business

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push

U.S. Senator Elizabeth Warren (D-MA) and Director of the United States Office of Management and Budget, Russell Vought. Kevin Mohatt | Kevin Lamarque | | Reuters Sen. Elizabeth Warren on Friday accused the acting head of the Consumer Financial Protection Bureau of undermining President Donald Trump’s stated push to make credit cards more affordable, according […]

Read More
Why a niche category of CRE lending is suddenly seeing record deals
Business

Why a niche category of CRE lending is suddenly seeing record deals

Wepro | Moment | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight […]

Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Business

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase […]

Read More